Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Creative Financial Designs Inc. ADV

Creative Financial Designs Inc. ADV cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 52.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,308 shares of the biopharmaceutical company’s stock after selling 1,432 shares during the quarter. Creative Financial Designs Inc. ADV’s holdings in Gilead Sciences were worth $121,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Bellevue Group AG boosted its holdings in shares of Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after buying an additional 7,093 shares during the period. Quantinno Capital Management LP boosted its stake in Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after acquiring an additional 48,910 shares during the period. McAdam LLC boosted its stake in Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after acquiring an additional 3,627 shares during the period. Capital Investment Advisors LLC raised its position in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after purchasing an additional 9,791 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in Gilead Sciences by 3.9% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock valued at $13,132,000 after purchasing an additional 5,382 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $105.87 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $131.84 billion, a PE ratio of 286.14, a PEG ratio of 0.71 and a beta of 0.21. The firm’s 50 day moving average price is $103.33 and its 200 day moving average price is $93.56. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of recent analyst reports. UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Oppenheimer raised their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Mizuho lifted their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.